HEMLIBRA® is the first and only subcutaneous injection for patients with hemophilia A with or without FVIII inhibitors

HEMLIBRA self-injection

Once trained by a healthcare provider, a patient may self-inject or use the help of a caregiver if a healthcare provider determines that it is appropriate.

  • Discontinue the prophylactic use of bypassing agents the day before starting HEMLIBRA prophylaxis
  • The prophylactic use of factor VIII (FVIII) products may be continued during the first week of HEMLIBRA prophylaxis
  • Do not combine HEMLIBRA vials of different concentrations in one injection to give the prescribed dose
  • Patients should follow recommendations in the Instructions for Use, including proper sharps disposal
  • HEMLIBRA is stored between 2ºC to 8ºC (36ºF to 46ºF) in the original carton to protect from light; the product should not be left out of refrigeration for more than a total of 7 days; do not freeze or shake
  • Self-administration is not recommended for children aged less than 7 years old

Injection Demonstration Video

A step-by-step video for your patients

Dosing Calculator 

Help calculate the dosage for your HEMLIBRA patient

Treating Breakthrough Bleeds

Guidelines for addressing breakthrough bleeds